Delving into the Latest Updates on Dashi Pharmaceutical (Guangdong) Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Immune System Diseases

Bispecific antibody

Monoclonal antibody

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Nervous System Diseases	2
Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Bispecific antibody	3
Monoclonal antibody	2
Antibody	1
Antibody drug conjugate (ADC)	1

Top 5 Target	Count

NGF(Nerve growth factor)	2
Trop-2(Tumor-associated calcium signal transducer 2)	1
HER2 x PDL1	1
CD276 x PDL1	1
ACE2(Angiotensin-converting enzyme 2)	1

Primary objective: To evaluate the safety and tolerability of DS002 injection in the treatment of bone metastasis pain. Secondary objectives: To evaluate the preliminary efficacy of DS002 injection in the treatment of moderate to severe bone metastasis pain; To evaluate the immunogenicity of DS002 in patients; To evaluate the pharmacokinetic (PK) characteristics of DS002 in subjects.

Start Date28 Sep 2022

Sponsor / Collaborator

Dashi Pharmaceutical (Guangdong) Co., Ltd.

CTR20210155

/ CompletedPhase 1

一项评价DS002注射液单次给药在健康受试者中的安全性、耐受性、药代动力学及免疫原性的随机、双盲、剂量递增、安慰剂对照的I期临床研究

[Translation] A randomized, double-blind, dose-escalation, placebo-controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of a single dose of DS002 injection in healthy subjects

主要目的是评价DS002在健康受试者中单次给药的安全性和耐受性，同时评价DS002在健康受试者中单次给药后的药代动力学（Pharmacokinetics, PK）特征和评价DS002在健康受试者中单次给药后的免疫原性，为后续试验推荐给药剂量。

[Translation]

The main objectives are to evaluate the safety and tolerability of a single dose of DS002 in healthy subjects, to evaluate the pharmacokinetic (PK) characteristics of DS002 after a single dose in healthy subjects, and to evaluate the immunogenicity of DS002 after a single dose in healthy subjects, so as to recommend a dosage for subsequent trials.

Start Date22 Feb 2021

Sponsor / Collaborator

Dashi Pharmaceutical (Guangdong) Co., Ltd.

100 Clinical Results associated with Dashi Pharmaceutical (Guangdong) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Dashi Pharmaceutical (Guangdong) Co., Ltd.

Login to view more data

1

Literatures (Medical) associated with Dashi Pharmaceutical (Guangdong) Co., Ltd.

Signal Transduction and Targeted Therapy

Construction of paclitaxel-based antibody–drug conjugates with a PEGylated linker to achieve superior therapeutic index

Letter

Author: Chen, Yuning ; Zhu, Tong ; Liu, Xiaoyue ; Li, Hui ; Wang, Qi ; Shao, Ting ; Ju, Dianwen ; Chen, Yi-Li ; Chen, Tianzhi ; Guo, Maojun ; Wang, Chunhe

A review.The selection of linkers and payloads plays a crucial role indetermining the therapeutic indexes of antibody-drug conjugates(ADCs).As paclitaxel (PTX) has been used therapeutically in pancreaticcancer and TNBC, in which Trop-2 is highly expressed, it appears to be a viable payload option for Trop-2-targeting ADCs.In cancer cell lines with diverse Trop-2 expression levels, our results indicated that free drug PTX is not as potent as MMAE, but similar to SN38.ADC mols. employing PTX, hydrophilic linkers, and Trop-2 antibodies showed superior efficacy and safety profile in vitro and in vivo, suggesting that it is a promising targeted therapeutic for human carcinomas.

100 Deals associated with Dashi Pharmaceutical (Guangdong) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Dashi Pharmaceutical (Guangdong) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

2

Preclinical

IND Application

1

2

IND Approval

Phase 2 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

DS-002 ( NGF )	Bone metastases More	Phase 2 Clinical
DS003(Tashi Pharmaceutical) ( CD47 )	Neoplasms More	IND Approval
DS001	Advanced cancer More	IND Approval
DS010 ( NGF )	Pain More	IND Application
DS-005	Neoplasms More	Preclinical